Clinical Trials

Our team is committed to developing new medicines to treat life-altering central nervous system (CNS) disorders. We are focused on advancing novel therapies through our understanding of the disease biology and translational findings. Our trials serve carefully selected patient populations who have limited treatment options.

Postpartum Depression

HUMMINGBIRD PROGRAM

Phase 3 trials evaluating a therapeutic candidate in the treatment of postpartum depression (PPD).

Sage is currently conducting two multi-center, randomized, double-blind, parallel-group, placebo-controlled Phase 3 studies evaluating the efficacy, safety and pharmacokinetics of brexanolone injection in the treatment of adult female subjects with moderate to severe postpartum depression. One of the Phase 3 studies is evaluating dose ranges of brexanolone in severe PPD patients and the other Phase 3 study is evaluating brexanolone treatment in moderate PPD patients.

Any travel required to participate in this trial will be paid for by Sage Therapeutics. For more information about this trial and participating locations, visit the Hummingbird Study website.

We are committed to respecting the primary role of healthcare providers in the treatment of CNS disorders. Therefore, we cannot respond to medical questions about your personal health situation, nor can we accept private medical information. Please contact your healthcare provider with any questions pertaining to your or a family member's medical condition.

Phase 2 Clinical Trials

Sage is evaluating our compounds as potential therapies for multiple CNS indications.

We are committed to respecting the primary role of healthcare providers in the treatment of CNS disorders. Therefore, we cannot respond to medical questions about your personal health situation, nor can we accept private medical information. Please contact your healthcare provider with any questions pertaining to your or a family member's medical condition